Free Trial
NASDAQ:TWST

Twist Bioscience (TWST) Stock Price, News & Analysis

Twist Bioscience logo
$26.59 -0.60 (-2.21%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$26.58 -0.02 (-0.06%)
As of 07:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Twist Bioscience Stock (NASDAQ:TWST)

Key Stats

Today's Range
$26.30
$27.50
50-Day Range
$25.00
$39.12
52-Week Range
$24.28
$55.33
Volume
1.54 million shs
Average Volume
1.95 million shs
Market Capitalization
$1.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.40
Consensus Rating
Moderate Buy

Company Overview

Twist Bioscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

TWST MarketRank™: 

Twist Bioscience scored higher than 79% of companies evaluated by MarketBeat, and ranked 220th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Twist Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 9 buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Twist Bioscience has only been the subject of 1 research reports in the past 90 days.

  • Read more about Twist Bioscience's stock forecast and price target.
  • Earnings Growth

    Earnings for Twist Bioscience are expected to grow in the coming year, from ($2.12) to ($1.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Twist Bioscience is -18.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Twist Bioscience is -18.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Twist Bioscience has a P/B Ratio of 3.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Twist Bioscience's valuation and earnings.
  • Percentage of Shares Shorted

    17.83% of the float of Twist Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Twist Bioscience has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Twist Bioscience has recently decreased by 2.88%, indicating that investor sentiment is improving.
  • Dividend Yield

    Twist Bioscience does not currently pay a dividend.

  • Dividend Growth

    Twist Bioscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.83% of the float of Twist Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Twist Bioscience has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Twist Bioscience has recently decreased by 2.88%, indicating that investor sentiment is improving.
  • News Sentiment

    Twist Bioscience has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Twist Bioscience this week, compared to 7 articles on an average week.
  • Search Interest

    7 people have searched for TWST on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Twist Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Twist Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $193,852.00 in company stock.

  • Percentage Held by Insiders

    Only 3.01% of the stock of Twist Bioscience is held by insiders.

  • Read more about Twist Bioscience's insider trading history.
Receive TWST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TWST Stock News Headlines

Twist Bioscience (TWST) Receives a Buy from Guggenheim
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
Twist Bioscience Appoints Trynka Shineman Blake to Board
Twist Bioscience: Headwinds Are Mounting
See More Headlines

TWST Stock Analysis - Frequently Asked Questions

Twist Bioscience's stock was trading at $46.47 on January 1st, 2025. Since then, TWST stock has decreased by 42.8% and is now trading at $26.59.

Twist Bioscience Corporation (NASDAQ:TWST) posted its quarterly earnings data on Monday, August, 4th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07. The company had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative trailing twelve-month return on equity of 29.03%.
Read the conference call transcript
.

Twist Bioscience (TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Twist Bioscience's top institutional shareholders include ARK Investment Management LLC (10.68%), Artisan Partners Limited Partnership (8.38%), William Blair Investment Management LLC (6.52%) and State Street Corp (4.14%). Insiders that own company stock include Emily M Leproust, William Banyai, Patrick John Finn, Paula Green, Dennis Cho, Adam Laponis, Robert F Werner and Robert Chess.
View institutional ownership trends
.

Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Twist Bioscience investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
8/04/2025
Today
8/29/2025
Fiscal Year End
9/30/2025
Next Earnings (Estimated)
11/17/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TWST
CIK
1581280
Fax
N/A
Employees
990
Year Founded
N/A

Price Target and Rating

High Price Target
$62.00
Low Price Target
$33.00
Potential Upside/Downside
+85.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$208.73 million
Net Margins
-23.51%
Pretax Margin
-23.41%
Return on Equity
-29.03%
Return on Assets
-21.77%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
3.90
Quick Ratio
3.60

Sales & Book Value

Annual Sales
$362.27 million
Price / Sales
4.43
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.92 per share
Price / Book
3.36

Miscellaneous

Outstanding Shares
60,361,000
Free Float
58,544,000
Market Cap
$1.60 billion
Optionable
Optionable
Beta
2.36

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:TWST) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners